Article
A University of Mississippi study of headaches among HIV patients is being hailed as a critical step to improving treatment and reducing unnecessary medical costs among sufferers.
.
The paper, "Headache among Patients with HIV Disease: Prevalence, Characteristics, and Associations," is being published in a forthcoming issue of the journal Headache and is already available online at http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4610.2011.02025.x/abstract
The results of the study show that headache affects one of every two HIV/AIDS patients, but these are not typical tension headaches. Approximately 27.5 percent of the patients studied met criteria for "chronic migraine," a rare headache condition in which a person has migraine symptoms — with or without other headaches – for 15 or more days per month. In comparison, only 2 percent of the general population is classified as having chronic migraines.
Read more at: http://www.newswise.com/articles/view/583668/?sc=dwhr&xy=10006693
Source: Newswise
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity
PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity
2 Commerce Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.